Alliance Pharma PLC Directorate Changes (3072G)
March 01 2018 - 2:02AM
UK Regulatory
TIDMAPH
RNS Number : 3072G
Alliance Pharma PLC
01 March 2018
For immediate release 1 March 2018
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Directorate Changes
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
group, announces the appointment of a new Chairman, the succession
of the Deputy CEO to CEO and the current CEO's transition to a
non-executive role.
CEO succession
Peter Butterfield, currently Deputy CEO, will take over from
John Dawson as CEO on 1 May 2018. John Dawson, who founded Alliance
in 1996, will remain on the Board as a Non-executive Director.
Peter Butterfield, Alliance's Deputy CEO, commented: "I am
delighted to be taking on the leadership of Alliance as it
continues to grow. It has been a real pleasure working alongside
John and I'm very pleased that he has decided to continue his
involvement with the Company as a Non-executive Director."
Appointment of Chairman
Alliance also announces that, following a search process
involving internal and external candidates, as of today David Cook,
a Non-executive Director of the Company for almost four years, will
take over as Non-executive Chairman from Andrew Smith, who will
today step down from Alliance's Board. David Cook is a chartered
accountant who worked in professional practice for 13 years with
PwC, following which he has worked for 14 years in the
pharmaceutical industry, including roles at EUSA Pharma Inc, Jazz
Pharmaceuticals Ltd and Biotie Therapies Corporation. He is
currently Chief Financial Officer of Ellipses Pharma Limited.
Commenting on the Board changes, John Dawson, Alliance's CEO,
said: "It has been enormously gratifying to have developed Alliance
over more than twenty years and to have grown the Company into a
successful international business. I look forward to continuing to
contribute to Alliance as a Non-executive Director.
"Peter Butterfield and I have worked closely together since he
joined Alliance following our acquisition of Cambridge Laboratories
eight years ago. His career path has been impressive and his
capabilities give the Board the utmost confidence that, as CEO,
Peter will be highly effective in driving the Company forward.
"David Cook has been an invaluable Board member over the past
four years and we are delighted that he has agreed to chair the
Board as the Company continues on its growth trajectory.
Additionally, on behalf of the Board, I would like to thank Andrew
Smith for his sound contribution to the Board over the past 11
years and in particular for his chairmanship since 2014. We wish
him well for the future."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Peter Butterfield, Deputy Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock
Investec Bank plc +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Rob Baker
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical group based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a wide network of distributors. Alliance
has a strong track record of acquiring the rights to established
niche products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPGUGCPUPRGMR
(END) Dow Jones Newswires
March 01, 2018 02:02 ET (07:02 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024